JP2018523686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523686A5 JP2018523686A5 JP2018508741A JP2018508741A JP2018523686A5 JP 2018523686 A5 JP2018523686 A5 JP 2018523686A5 JP 2018508741 A JP2018508741 A JP 2018508741A JP 2018508741 A JP2018508741 A JP 2018508741A JP 2018523686 A5 JP2018523686 A5 JP 2018523686A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- diabody
- cell carcinoma
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562206051P | 2015-08-17 | 2015-08-17 | |
| US62/206,051 | 2015-08-17 | ||
| US201662280318P | 2016-01-19 | 2016-01-19 | |
| US62/280,318 | 2016-01-19 | ||
| PCT/US2016/046680 WO2017030926A1 (en) | 2015-08-17 | 2016-08-12 | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523686A JP2018523686A (ja) | 2018-08-23 |
| JP2018523686A5 true JP2018523686A5 (enExample) | 2019-08-08 |
Family
ID=58051498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508741A Pending JP2018523686A (ja) | 2015-08-17 | 2016-08-12 | Ｂ７‐ｈ３及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20190002563A1 (enExample) |
| EP (1) | EP3337507A4 (enExample) |
| JP (1) | JP2018523686A (enExample) |
| KR (1) | KR20180038045A (enExample) |
| CN (1) | CN107921130A (enExample) |
| AU (1) | AU2016307955A1 (enExample) |
| CA (1) | CA2995709A1 (enExample) |
| CL (1) | CL2018000422A1 (enExample) |
| CO (1) | CO2018001485A2 (enExample) |
| CR (1) | CR20180105A (enExample) |
| EA (1) | EA201890443A1 (enExample) |
| EC (1) | ECSP18011248A (enExample) |
| HK (1) | HK1249423A1 (enExample) |
| IL (1) | IL257562A (enExample) |
| MA (1) | MA42665A (enExample) |
| MX (1) | MX2018001954A (enExample) |
| PE (1) | PE20181066A1 (enExample) |
| PH (1) | PH12018500363A1 (enExample) |
| TW (1) | TW201718652A (enExample) |
| WO (1) | WO2017030926A1 (enExample) |
| ZA (1) | ZA201800955B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| MX375669B (es) | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| AU2018224094B2 (en) | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| SG11201909160WA (en) | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN111356700A (zh) * | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | 受约束的条件性活化的结合蛋白 |
| CN109939232A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用 |
| CN109939231A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用 |
| CN109939126A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用 |
| CN109939230A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用 |
| CN109971711A (zh) * | 2017-12-27 | 2019-07-05 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用 |
| JP7337079B2 (ja) | 2018-02-15 | 2023-09-01 | マクロジェニクス，インコーポレーテッド | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
| KR20260046525A (ko) | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| CN120623346A (zh) | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| TW202033218A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 多特異性蛋白分子 |
| MX2021006389A (es) * | 2018-12-07 | 2021-07-15 | Jiangsu Hengrui Medicine Co | Anticuerpo cd3 y uso farmaceutico del mismo. |
| KR102732027B1 (ko) * | 2019-07-09 | 2024-11-20 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
| CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技（成都）有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
| EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
| CN114901306A (zh) * | 2019-12-23 | 2022-08-12 | 宏观基因有限公司 | 用于治疗癌症的疗法 |
| JP7789002B2 (ja) | 2020-01-29 | 2025-12-19 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物 |
| MX2023000662A (es) * | 2020-07-17 | 2023-02-27 | Pfizer | Anticuerpos terapeuticos y sus usos. |
| EP4032910A1 (en) * | 2021-01-22 | 2022-07-27 | ETH Zurich | Bispecific binding agent that binds to cd3 and a fluorophore |
| CN117751145A (zh) * | 2021-04-28 | 2024-03-22 | 礼进生物医药科技（上海）有限公司 | 包括抗b7h3结合分子的双特异性抗体 |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CN114539420B (zh) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
| WO2025245264A1 (en) * | 2024-05-21 | 2025-11-27 | Briapro Therapeutics Corp. | Anti-b7-h3 antibodies and methods of use thereof |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2542256B1 (en) * | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| US10851178B2 (en) * | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| BR112018006817A2 (pt) * | 2015-10-08 | 2018-10-23 | Macrogenics Inc | método de tratamento do câncer |
-
2016
- 2016-08-12 US US15/752,367 patent/US20190002563A1/en not_active Abandoned
- 2016-08-12 KR KR1020187007443A patent/KR20180038045A/ko not_active Withdrawn
- 2016-08-12 EP EP16837560.8A patent/EP3337507A4/en not_active Withdrawn
- 2016-08-12 CA CA2995709A patent/CA2995709A1/en not_active Abandoned
- 2016-08-12 HK HK18109035.8A patent/HK1249423A1/zh unknown
- 2016-08-12 JP JP2018508741A patent/JP2018523686A/ja active Pending
- 2016-08-12 PE PE2018000249A patent/PE20181066A1/es unknown
- 2016-08-12 MA MA042665A patent/MA42665A/fr unknown
- 2016-08-12 CN CN201680048182.7A patent/CN107921130A/zh active Pending
- 2016-08-12 EA EA201890443A patent/EA201890443A1/ru unknown
- 2016-08-12 AU AU2016307955A patent/AU2016307955A1/en not_active Abandoned
- 2016-08-12 MX MX2018001954A patent/MX2018001954A/es unknown
- 2016-08-12 CR CR20180105A patent/CR20180105A/es unknown
- 2016-08-12 WO PCT/US2016/046680 patent/WO2017030926A1/en not_active Ceased
- 2016-08-16 TW TW105126154A patent/TW201718652A/zh unknown
-
2018
- 2018-02-13 ZA ZA2018/00955A patent/ZA201800955B/en unknown
- 2018-02-15 EC ECIEPI201811248A patent/ECSP18011248A/es unknown
- 2018-02-15 PH PH12018500363A patent/PH12018500363A1/en unknown
- 2018-02-15 IL IL257562A patent/IL257562A/en unknown
- 2018-02-15 CO CONC2018/0001485A patent/CO2018001485A2/es unknown
- 2018-02-15 CL CL2018000422A patent/CL2018000422A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523686A5 (enExample) | ||
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| CN108473565B (zh) | Ctla4结合剂 | |
| CN109071639B (zh) | Pd1/ctla4结合剂 | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2020508317A5 (enExample) | ||
| JP2020183413A (ja) | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 | |
| CN111133005B (zh) | 程序性细胞死亡蛋白1抗体 | |
| AU2018263862A1 (en) | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| JP2020536109A5 (enExample) | ||
| JP2016509582A5 (enExample) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP7459058B2 (ja) | Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法 | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| WO2023281480A1 (en) | Conjugates of checkpoint inhibitors with il-2, and uses thereof | |
| JP2022541591A5 (enExample) | ||
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| US20230032465A1 (en) | Antibody-drug conjugates specific for cd276 and uses thereof | |
| CN111655725A (zh) | 用于治疗癌症的组合产品 | |
| WO2024145869A1 (en) | Antibodies against axl and uses thereof | |
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| Lacek et al. | Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action | |
| JP2019531254A5 (enExample) | ||
| WO2025088496A1 (en) | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein |